Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.


Journal

Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372

Informations de publication

Date de publication:
07 2020
Historique:
received: 15 04 2020
accepted: 22 04 2020
pubmed: 23 5 2020
medline: 7 7 2020
entrez: 23 5 2020
Statut: ppublish

Résumé

Acute lung injury (ALI) represents the most severe form of the viral infection sustained by coronavirus disease 2019 (COVID-19). Today, it is a pandemic infection, and even if several compounds are used as curative or supportive treatment, there is not a definitive treatment. In particular, antiviral treatment used for the treatment of several viral infections (eg, hepatitis C, HIV, Ebola, severe acute respiratory syndrome-coronavirus) are today used with a mild or moderate effect on the lung injury. In fact, ALI seems to be related to the inflammatory burst and release of proinflammatory mediators that induce intra-alveolar fibrin accumulation that reduces the gas exchange. Therefore, an add-on therapy with drugs able to reduce inflammation, edema, and cell activation has been proposed as well as a treatment with interferon, corticosteroids or monoclonal antibodies (eg, tocilizumab). In this article reviewing literature data related to the use of escin, an agent having potent anti-inflammatory and anti-viral effects in lung injury, we suggest that it could represent a therapeutic opportunity as add-on therapy in ALI related to COVID-19 infection.

Identifiants

pubmed: 32441805
doi: 10.1002/jcph.1644
pmc: PMC7280635
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Antiviral Agents 0
Immunologic Factors 0
Inflammation Mediators 0
Escin 6805-41-0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

815-825

Informations de copyright

© 2020, The American College of Clinical Pharmacology.

Références

Int J Occup Environ Med. 2020 Feb 5;11(2):65-71
pubmed: 32020915
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Pharmacol Res. 2020 Jun;156:104761
pubmed: 32205232
Thromb Haemost. 2008 Mar;99(3):494-501
pubmed: 18327397
Fa Yi Xue Za Zhi. 2020 Apr;36(2):157-163
pubmed: 32212512
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670
pubmed: 32196083
CMAJ. 2020 Apr 27;192(17):E450-E453
pubmed: 32269021
Science. 1985 Mar 22;227(4693):1487-90
pubmed: 4038818
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Drug Des Devel Ther. 2019 Sep 27;13:3425-3437
pubmed: 31631970
Trials. 2020 Jan 3;21(1):8
pubmed: 31900204
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
Virol Sin. 2020 Jun;35(3):266-271
pubmed: 32125642
J Pharm Pharmacol. 2018 Nov;70(11):1561-1571
pubmed: 30168142
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Exp Lung Res. 2011 Dec;37(10):585-99
pubmed: 22087513
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Clin Pharmacol Ther. 2020 Aug;108(2):242-247
pubmed: 32246834
Int J Antimicrob Agents. 2020 May;55(5):105938
pubmed: 32171740
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
J Clin Invest. 1989 Aug;84(2):695-705
pubmed: 2788176
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Am Rev Respir Dis. 1989 Aug;140(2):513-24
pubmed: 2669580
Oncologist. 2018 Aug;23(8):943-947
pubmed: 29622697
Lancet. 2020 Feb 15;395(10223):e30-e31
pubmed: 32032529
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Trials. 2018 Jan 30;19(1):81
pubmed: 29382391
J Infect. 2020 Jul;81(1):e1-e5
pubmed: 32171872
PLoS One. 2016 Oct 11;11(10):e0164365
pubmed: 27727329
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018 Jul;34(7):600-604
pubmed: 30381123
Arch Pathol Lab Med. 1976 Mar;100(3):147-53
pubmed: 946402
Expert Rev Clin Immunol. 2019 Aug;15(8):813-822
pubmed: 31219357
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7
pubmed: 15226499
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-172
pubmed: 32164080
F1000Res. 2020 Feb 21;9:129
pubmed: 32194944
EMBO J. 2005 Apr 20;24(8):1634-43
pubmed: 15791205
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Am J Respir Cell Mol Biol. 1996 Jan;14(1):53-60
pubmed: 8534486
Planta Med. 2007 Mar;73(3):285-8
pubmed: 17310430
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
Semin Immunopathol. 2017 Jul;39(5):517-528
pubmed: 28555385
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Emerg Med J. 2006 Jun;23(6):421-4
pubmed: 16714497
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
Phytomedicine. 2011 Feb 15;18(4):272-7
pubmed: 20850956
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Eur J Pharm Sci. 2011 Jan 18;42(1-2):73-80
pubmed: 21040784
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Mil Med Res. 2020 Feb 6;7(1):4
pubmed: 32029004
Science. 2005 Sep 16;309(5742):1864-8
pubmed: 16166518
Antiviral Res. 2019 Apr;164:1-11
pubmed: 30711418
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Crit Care Med. 2020 Feb;48(2):e98-e106
pubmed: 31939808
Anesthesiology. 2020 Apr;132(4):795-807
pubmed: 32101978
Arch Acad Emerg Med. 2020 Mar 30;8(1):e40
pubmed: 32259129
J Cell Physiol. 2007 Feb;210(2):489-97
pubmed: 17044077
FEBS Open Bio. 2019 May;9(5):891-900
pubmed: 30972964
Inhal Toxicol. 2014 Feb;26(3):185-92
pubmed: 24517841
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Antiviral Res. 2018 Feb;150:202-216
pubmed: 29325970
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Thorac Oncol. 2020 May;15(5):700-704
pubmed: 32114094
Lancet Infect Dis. 2003 Nov;3(11):722-7
pubmed: 14592603
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
Lancet Infect Dis. 2006 Feb;6(2):67-9
pubmed: 16439323
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
J Pathol. 2006 Nov;210(3):288-97
pubmed: 17031779
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342
pubmed: 32202240

Auteurs

Luca Gallelli (L)

Department of Health Science, University of Catanzaro, Italy and Operative Unit of Clinical Pharmacology Mater Domini Hospital, Catanzaro, Italy.

Leiming Zhang (L)

School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, China.

Tian Wang (T)

School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, China.

Fenghua Fu (F)

School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH